Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Pleural Effusion, Malignant 3Immunoglobulin Light-chain Amyloidosis 3Colorectal Neoplasms 3Breast Neoplasms 3Mycosis Fungoides 2Lymphoma, Non-Hodgkin 2Amyloidosis 2Waldenstrom Macroglobulinemia 1Urologic Neoplasms 1Tuberous Sclerosis 1Tissue Adhesions 1Skin Toxicity 1Sezary Syndrome 1Ras-wildtype Colorectal Cancer 1Polyps 1Polycystic Ovary Syndrome 1Pleural Neoplasms 1Pancreatic Neoplasms 1Pain 1Neurofibromatosis 2 1Neoplasms, Second Primary 1Myoma 1Menstruation Disturbances 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1

Interventions

Nivolumab 146Ipilimumab 137pembrolizumab 122Cyclophosphamide 78Interleukin-2 69aldesleukin 63Temozolomide 46trametinib 37Radiosurgery 37Vemurafenib 36fludarabine 34Biopsy 34dabrafenib 33Radiotherapy 33Blood Specimen Collection 31fludarabine phosphate 30sargramostim 27Bevacizumab 27Introns 23Dacarbazine 22Magnetic Resonance Spectroscopy 21Specimen Handling 20CTLA-4 Antigen 20encorafenib 19cobimetinib 19binimetinib 19Paclitaxel 19Granulocyte-Macrophage Colony-Stimulating Factor 19Cisplatin 17incomplete Freund's adjuvant 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Melanoma × Doxycycline × Clear all
NCT01590082 2020-09-02

Doxycycline, Temozolomide and Ipilimumab in Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
12 enrolled 6 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡